Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

Le résumé fourni par la source

Abstract Introduction: While CD19-directed Chimeric Antigen Receptor (CAR) T-cell therapy is now established as a standard of care in relapsed/refractory B-cell lymphoma, we and others showed its feasibility and effectiveness in adult and adolescent patients with refractory systemic lupus erythematosus (SLE) (Mackensen et al., Nat Med 2022; Müller et al., NEJM 2024; Krickau et al., Lancet 2024). Furthermore, we recently demonstrated that - despite similar CAR T-cell kinetics – patients with SLE experience less severe adverse events than patients with B-cell lymphoma (Müller et al., Blood 2025). While side effects of CAR T-cell therapy are widely studied, resolution of CAR T-cell-induced but also disease-specific inflammation is still poorly understood. Methods: We performed deep serum proteomics in SLE patients (N=18; all patients in CR) and lymphoma patients [DLBCL NOS (N=39), MCL (N=3), other types of NHL (N=6); 50% in lasting CR > 6 months] before and at day +7, +14, +30, +90, and +365 after CAR T-cell therapy. In addition, healthy control samples of age-matched donors (SLE controls: n=18; lymphoma controls: n=30) were also analyzed. Persistence of CAR T-cells within patients and reconstitution of T- and B-cells were measured by flow cytometry and linked to serum proteome profiles. All patients received either commercial CAR T-cell products or the investigational medicinal product MB-CART19.1 (in-house manufactured 2nd generation anti-CD19 CAR T-cells with a 4.1BB co-stimulatory domain) in our center. Results: To characterize inflammatory signatures, we performed serum proteomics using the Olink® Target 96 Immuno-Oncology Panel across the CAR T-cell treatment course. Prior to CAR T-cell therapy, both B-cell lymphoma and SLE patients exhibit an inflammatory serum milieu - characterized by elevated levels of IL-6, IL-1α, IFN-γ, and CXCL10 - compared to age- and sex-matched healthy donors (HDs). One-year after CAR T-cell therapy, lymphoma patients maintained elevated pro-inflammatory cytokine levels compared to HDs, whereas SLE patients demonstrated resolution of IL-6-driven inflammation and reduction of SLE-associated cytokines including IL-8, CXCL13, MCP-1, and MCP-3. Concurrently, SLE patients showed increased expression of cytokines linked to immune cell reconstitution (TGF-b1, TRAIL, CXCL5, CXCL12, IL-7). This immune-restorative shift coincided with the loss of CAR T-cell persistence in SLE patients, suggesting a link between the persistence of CAR T-cells and resolution of inflammation. Principal component analysis (PCA) of serum proteins identified that angiogenic markers ANGPT-1 and VEGF-2 as well as immune-reconstituting cytokines CXCL5 and CXCL12, contributed to distinct clustering of SLE patients one-year post-CAR T-cell therapy, aligning them more closely with HDs. In contrast, no such clustering was observed in B-cell lymphoma patients prior to or post CAR T-cell therapy compared with HDs. Notably, the shift of cytokine expression and the resolution of IL-6–driven inflammation in SLE patients are further supported by the rapid reconstitution of T and B cells after CAR T-cell therapy, with upregulated serum IL-7 and CXCL12 likely contributing to T-cell and B-cell recovery, respectively. This pattern was specific to SLE patients, whereas persistent inflammation and ongoing B-cell aplasia could be observed in patients with B-cell lymphoma. Conclusion: Taken together, our data reveal a resolution of systemic inflammation specific to SLE patients following CAR T-cell therapy, compared to patients with B-cell lymphoma. This resolution might be linked to the shorter persistence of CAR T-cells in SLE patients and thus benefit the reconstitution of the adaptive immune system.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.